A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)

Inclusion Criteria:

- Male or female subjects, age 18 years or older

- Subjects with histologically or cytologically confirmed NSCLC, MEL (including I/O
relapsed MEL or I/O refractory MEL), CRC, SCCHN, ovarian cancer, recurrent B cell NHL
or HL, or glioblastoma

- Presence of measurable disease by RECIST v1.1 for solid tumors or Cheson criteria for
B cell NHL (including DLBCL) or HL. For subjects with glioblastoma, presence of
measurable disease is not required.

- Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1

- Fresh baseline tumor biopsies (defined as a biopsy specimen taken since completion of
the most recent prior chemotherapy regimen) are required for all cohorts except
glioblastoma

Exclusion Criteria:

- Laboratory and medical history parameters not within Protocol-defined range

- Currently pregnant or breastfeeding

- Subjects who have received prior immune checkpoint inhibitors or an IDO inhibitor
(except select Phase 2 cohorts evaluating I/O relapsed or I/O refractory MEL).
Subjects who have received experimental vaccines or other immune therapies should be
discussed with the medical monitor to confirm eligibility

- Untreated central nervous system (CNS) metastases or CNS metastases that have
progressed

- Subjects with any active or inactive autoimmune process

- Evidence of interstitial lung disease or active, noninfectious pneumonitis

- Subjects with any active or inactive autoimmune process

- Ocular MEL